Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q1 2020
Top Holdings43 positions
IMMUNOMEDICS INC | 24.5M | $330.3M | 11.1% | — | — | 5 qtrssince 2019-Q1 | Unchanged 0 |
MIRATI THERAPEUTICS INC | 4.1M | $316.1M | 10.7% | — | — | 5 qtrssince 2019-Q1 | Increased 65 |
IOVANCE BIOTHERAPEUTICS INC COM | 9M | $269.7M | 9.1% | $10.23 | +192.63% | 5 qtrssince 2019-Q1 | Increased 62 |
ASCENDIS PHARMA A/S | 1.8M | $201.2M | 6.8% | $117.47 | -1.25% | 5 qtrssince 2019-Q1 | Decreased 0 |
BIOMARIN PHARMACEUTICAL INC | 1.9M | $163.1M | 5.5% | $84.82 | -2.75% | 5 qtrssince 2019-Q1 | Decreased 0 |
SAREPTA THERAPEUTICS INC | 1.6M | $155M | 5.2% | $116.47 | -15.41% | 5 qtrssince 2019-Q1 | Decreased 0 |
HORIZON THERAPEUTICS PUB L | 4.6M | $135.5M | 4.6% | — | — | 4 qtrssince 2019-Q2 | Increased 64 |
KARYOPHARM THERAPEUTICS INC | 7M | $134.5M | 4.5% | — | — | — | Increased 66 |
ARGENX SE | 936,500 | $123.4M | 4.2% | $128.71 | +2.35% | 5 qtrssince 2019-Q1 | Unchanged 0 |
CONSTELLATION PHARMCETICLS I | 3.7M | $114.7M | 3.9% | — | — | 2 qtrssince 2019-Q4 | Unchanged 0 |
AMICUS THERAPEUTICS INC | 11M | $101.2M | 3.4% | $12.97 | -25.14% | 5 qtrssince 2019-Q1 | Decreased 0 |
DECIPHERA PHARMACEUTICALS IN | 2M | $82.3M | 2.8% | — | — | 2 qtrssince 2019-Q4 | Increased 83 |
UNIQURE NV | 1.7M | $78.3M | 2.6% | $64.73 | -26.69% | 3 qtrssince 2019-Q3 | Decreased 0 |
ACCELERON PHARMA INC | 860,000 | $77.3M | 2.6% | — | — | 1 qtr | New 78 |
ADVERUM BIOTECHNOLOGIES INC | 7.2M | $69.9M | 2.4% | — | — | — | Increased 67 |
ZOGENIX INC | 2.8M | $69.2M | 2.3% | — | — | 5 qtrssince 2019-Q1 | Increased 68 |
MYOKARDIA INC | 1.4M | $67.3M | 2.3% | — | — | 5 qtrssince 2019-Q1 | Decreased 0 |
PTC THERAPEUTICS INC | 1.2M | $53.5M | 1.8% | $42.54 | 0.00% | 1 qtr | New 68 |
RELMADA THERAPEUTICS INC COM | 1.2M | $39.2M | 1.3% | $31.76 | 0.00% | 1 qtr | New 67 |
ATHENEX INC | 4.9M | $37.7M | 1.3% | — | — | 4 qtrssince 2019-Q2 | Decreased 0 |
Avoro Capital Advisors LLC manages $3B across 43 positions as of Q1 2020. Top holdings: IMMU (11.1%), MRTX (10.7%), IOVA (9.1%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.
Active quarter - 12 new positions, 0 exits, 9 increased. Top move: DCPH (INCREASED, conviction 83). Portfolio: $3.0B across 43 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR